1152914-16-3

Basic information

• Product Name: 2-(4-amino-1H-pyrazol-1-yl)-1-(morpholin-4-yl)ethan-1-one
• Synonyms: 2-(4-amino-1H-pyrazol-1-yl)-1-(morpholin-4-yl)ethan-1-one
• CAS NO: 1152914-16-3
• Molecular Formula: C₉H₁₄N₄O₂
• Molecular Weight: 210.23
• Mol File: 1152914-16-3.mol
• Article Data: 3

Chemical Properties

• Boiling Point: 471.3±45.0 °C(Predicted)
• Appearance: /
• Density: 1.42±0.1 g/cm3(Predicted)
• PKA: 3.38±0.11(Predicted)
• CAS DataBase Reference: 2-(4-amino-1H-pyrazol-1-yl)-1-(morpholin-4-yl)ethan-1-one(CAS DataBase Reference)
• NIST Chemistry Reference: 2-(4-amino-1H-pyrazol-1-yl)-1-(morpholin-4-yl)ethan-1-one(1152914-16-3)
• EPA Substance Registry System: 2-(4-amino-1H-pyrazol-1-yl)-1-(morpholin-4-yl)ethan-1-one(1152914-16-3)

Safety Data

• Hazardous Substances Data: 1152914-16-3(Hazardous Substances Data)

Usage

Type of compound

Synthetic organic compound

Potential applications

Pharmaceutical

+ Pyrazole ring

A five-membered heterocyclic ring with two nitrogen atoms

+ Amino group

A functional group with a nitrogen atom and two hydrogen atoms

+ Morpholine group

A five-membered heterocyclic ring with four oxygen atoms and one nitrogen atom

Biological activity

Potential antitumor and antimicrobial properties

Additional research needed

Further studies required to understand the compound's potential uses and effects

Upstream product

• 40299-87-4 N-(bromoacetyl)morpholine 

Relevant articles and documents

Design, synthesis and biological evaluation of novel 7H-pyrrolo[2,3-d]pyrimidine derivatives as potential FAK inhibitors and anticancer agents

A series of 7H-pyrrolo[2,3-d]pyrimidine derivatives possessing a dimethylphosphine oxide moiety were designed, synthesized and evaluated as novel Focal adhesion kinase (FAK) inhibitors. Most compounds potently suppressed the enzymatic activities of FAK, with IC50 values in the 10?8–10?9 M range, and potently inhibited the proliferation of breast (MDA-MB-231) and lung (A549) cancer cell lines. The representative compound 25b exhibited potent enzyme inhibition (IC50 = 5.4 nM) and good selectivity when tested on a panel of 26 kinases. 25b exhibited antiproliferative activity against A549 cells (IC50 = 3.2 μM) and relatively less cytotoxicity to a normal human cell line HK2. Compound 25b also induced apoptosis and suppressed the migration of A549 cells in a concentration-dependent manner. Further profiling of compound 25b revealed it had good metabolic stability in mouse, rat and human liver microsomes in vitro and showed weak inhibitory activity against various subtypes of human cytochrome P450. The docking study of compound 25b was performed to elucidate its possible binding modes and to provide a structural basis for further structure-guided design of FAK inhibitors.

HETEROCYCLYL PYRAZOLOPYRIMIDINE ANALOGUES AS JAK INHIBITORS

The present invention relates to compounds of formula (I) wherein X1 to X5, Y, Z1 to Z3, and R have the meaning as cited in the description and the claims. Said compounds are useful as JAK inhibitors for the treatment or prophylaxis of immunological, inflammatory, autoimmune, allergic disorders, and immunologically-mediated diseases. The invention also relates to pharmaceutical compositions including said compounds, the preparation of such compounds as well as the use as medicaments.